MedicineOncologyPharmacologyCancer PharmacologyCutaneous OncologyMolecular OncologyBasal Cell CarcinomaCombination Cancer TherapyHedgehog SignalingImmunotherapy For Skin CancerMelanoma PharmacotherapySquamous Cell CarcinomaAdvanced Basal Cell Carcinoma TherapyBasal Cell Carcinoma ImmunotherapyHedgehog MedicineHedgehog Pathway InhibitorsHedgehog Signaling InhibitionMalignant Melanocytic TumorsPharmacological Targeting Of Hedgehog SignalingTriple Combination Therapy
Vismodegib, a potent inhibitor of the hedgehog pathway, is an effective treatment for advanced basal cell carcinoma. More recently, it has become recognized that other oral and topical medications exist that also inhibit this pathway. Multifocal inhibition has been shown to work more efficaciously than a single pathway inhibition when treating melanocytic tumors. The authors report the successful treatment of a patient with advanced basal cell carcinoma using the combination of vismodegib, itraconazole, and imiquimod, each of which inhibits a different part of the hedgehog pathway.
8
Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma
Aleksandar Sekulić, Michael R. Migden, Anthony E. Oro et al. · New England Journal of Medicine · 2012 · 1.4K citations · Full text
Medicine, Oncology, Pharmacology +17
Itraconazole, a Commonly Used Antifungal that Inhibits Hedgehog Pathway Activity and Cancer Growth
James Kim, Jean Y. Tang, Ruoyu Gong et al. · Cancer Cell · 2010 · 519 citations · Full text
Medicine, Oncology, Pharmacology +14